Inhibrx announces positive interim results from HexAgon trial
The Phase II segment enrolled 68 patients, with 33 assigned to the combination arm and 35 to the pembrolizumab-only arm.
News
Day One concludes patient enrolment for tovorafenib’s FIREFLY-2 trial
MEDSIR reports PHERGain and PHERGain-2 trial results for breast cancer
Patient enrolment concludes in Alebund’s Phase III trial of AP301
Nocion completes patient enrolment in Phase IIb ASPIRE trial
Takeda’s Phase II/III trial of TAK-881 meets primary endpoint
Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer
Merck KGaA doses first patient in Phase III programme of enpatoran
